Alembic Pharmaceuticals Limited — Important, 07-11-2024: Financial Result Updates

Alembic Pharmaceuticals Limited's Board approved the unaudited financial results for the quarter and half-year ended September 30, 2024. Key highlights include consolidated revenue from operations of ₹3,209.71 crores and profit after tax of ₹288.12 crores, reflecting robust performance. An exceptional income of ₹12.87 crores was recognized due to insurance claims related to previous disruptions. The company's debt-to-equity ratio stands at 0.20, indicating strong financial stability. Further details include cash flow and asset reports.